Sunshine Biopharma, Inc. (SBFM) Key Metrics
SBFM valuation today
Trailing 12 months · as of October 17, 2026- Market cap
- $3.3M
- Enterprise value
- −$9.5M
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- 0.1
- Price / book
- 0.1
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- 1.35
SBFM key metrics, 2016–2025
Fiscal year ended December 31, 2025 · U.S. dollarsSBFM returns How much profit the business earns on the capital it uses.
SBFM financial health Debt, liquidity and how easily interest is covered.
SBFM efficiency & capital use Working capital cycle and where the cash goes.
SBFM returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
SBFM debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
SBFM cash returned to shareholders
SBFM key metrics
2016–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Share price at fiscal year-end | $12.30 | $30.00 | $5,440.00 | $12,800.00 | $1,170.00 | $314.00 | $10.00 | $12.00 | $12.00 | $12.00 |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | −25.7% | −23.0% | −21.0% | −244.9% | — | — | — | — | — | — |
| Return on invested capital (ROIC) | −24.0% | −45.1% | −123.2% | — | — | — | — | −204.1% | — | — |
| Return on assets (ROA) | −19.7% | −17.7% | −15.8% | −168.5% | −765.7% | −486.9% | −266.8% | −307.1% | −646.3% | −948.0% |
| Return on tangible assets | −21.2% | −18.6% | −17.4% | −93.0% | −564.6% | −266.3% | — | −448.4% | −404.0% | — |
| Free cash flow margin | −15.2% | −42.6% | −39.7% | −127.8% | −800.8% | −922.1% | — | −118.9% | — | — |
| Financial health | ||||||||||
| Total debt | $812,422 | $952,480 | $657,705 | $765,258 | $1.9M | $1.9M | $715,568 | $952,604 | $802,319 | $236,971 |
| Cash & short-term investments | $9.1M | $9.7M | $16.3M | $21.8M | $2.0M | $997,478 | $48,091 | $115,216 | $107,532 | $57,453 |
| Net debt | −$8.3M | −$8.7M | −$15.6M | −$21.1M | −$145,167 | $915,643 | $667,477 | $837,388 | $694,787 | $179,518 |
| Debt / equity | 0.04 | 0.04 | 0.03 | 0.04 | 8.98 | — | — | — | — | — |
| Debt / assets | 0.03 | 0.03 | 0.02 | 0.03 | 0.86 | 1.83 | 7.29 | 0.83 | 3.12 | 3.68 |
| Current ratio | 4.17 | 4.11 | 4.48 | 3.94 | 24.07 | 0.98 | 0.08 | 0.23 | 0.16 | 0.21 |
| Quick ratio | 2.08 | 2.33 | 3.45 | 3.47 | 22.91 | 0.95 | 0.06 | 0.23 | 0.17 | 0.21 |
| Interest coverage | — | -662.4 | -34.9 | -220.1 | -7.4 | -3.4 | -5.5 | -7.3 | -8.2 | -28.6 |
| Working capital | $20.4M | $19.7M | $19.3M | $20.4M | $2.1M | −$25,362 | −$767,841 | −$700,965 | −$633,939 | −$215,644 |
| Invested capital | $14.7M | $14.8M | $5.6M | $566,391 | $66,495 | −$39,194 | −$67,908 | $781,635 | $121,424 | −$30,182 |
| Tangible asset value | $21.1M | $20.5M | $19.8M | $20.9M | $211,662 | −$954,837 | −$735,385 | −$721,450 | −$573,363 | −$209,700 |
| Net current asset value | $19.8M | $18.9M | $18.8M | $19.4M | $204,601 | −$974,368 | −$767,841 | −$990,812 | −$713,649 | −$215,644 |
| Capital allocation | ||||||||||
| Dividends paid | — | — | — | — | — | $0 | $0 | $0 | — | — |
| Share buybacks (net) | $0 | $3.1M | $541,143 | $99,000 | $0 | — | — | — | $0 | $0 |
| Capex / revenue | 0.5% | 6.7% | 3.3% | 7.0% | 0.0% | 1.7% | 4.1% | 4.2% | — | — |
| Capex / depreciation | 0.53 | 10.38 | 5.28 | 12.12 | 0.00 | 0.08 | 0.06 | 0.38 | 0.56 | 0.06 |
| Stock-based compensation / revenue | — | — | — | −0.1% | 401.9% | 70.0% | 1,239.0% | 151.2% | — | — |
| R&D / revenue | 1.7% | 2.7% | 7.7% | 18.7% | 294.3% | 2.4% | 72.0% | 2.9% | — | — |
| SG&A / revenue | 50.9% | 42.8% | 45.0% | 218.1% | 816.8% | 849.5% | 2,948.4% | 270.0% | — | — |
| Efficiency | ||||||||||
| Days sales outstanding | 36.8 | 33.6 | 33.8 | 80.6 | 7.8 | 6.0 | 824.2 | 42.7 | — | — |
| Days of inventory on hand | 185.3 | 128.3 | 104.5 | 233.9 | 200.5 | 280.2 | 525.5 | — | -532.3 | — |
| Days payables outstanding | 83.9 | 61.3 | 62.4 | 196.1 | 163.9 | 1,128.0 | 3,513.1 | 63.1 | 1,305.9 | 224.5 |
| Cash conversion cycle (days) | 138.2 | 100.6 | 75.9 | 118.5 | 44.3 | -841.8 | -2,163.3 | -20.4 | — | — |
| Receivables turnover | 9.91 | 10.86 | 10.79 | 4.53 | 47.03 | 60.88 | 0.44 | 8.55 | 0.00 | — |
| Payables turnover | 4.35 | 5.96 | 5.85 | 1.86 | 2.23 | 0.32 | 0.10 | 5.79 | 0.28 | 1.63 |
| Inventory turnover | 1.97 | 2.85 | 3.49 | 1.56 | 1.82 | 1.30 | 0.69 | — | — | — |
| Asset turnover | 1.20 | 1.20 | 0.85 | 0.27 | 0.14 | 0.12 | 0.03 | 0.64 | 0.00 | 0.00 |
| Average receivables | $3.7M | $3.2M | $2.2M | $959,976 | $4,857 | $1,173 | $47,692 | $52,311 | $9,667 | — |
| Average payables | $5.6M | $4.1M | $2.7M | $1.4M | $52,906 | $79,876 | $106,354 | $67,570 | $23,718 | $37,356 |
| Average inventory | $12.4M | $8.5M | $4.5M | $1.7M | $64,710 | $19,840 | $15,910 | — | −$9,667 | — |
| Intangibles / total assets | 6.3% | 9.9% | 5.3% | 2.6% | 0.0% | 0.0% | 0.0% | 58.1% | 0.0% | 0.0% |
Computed from SBFM's annual financial statements (latest annual report filed April 3, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
SBFM valuation and financial ratios
Sunshine Biopharma earned a return on equity of −25.7% and a return on invested capital of −24.0% in fiscal 2025. It ended the year with $0.8 million of debt and $9.1 million in cash and short-term investments, a net cash position of $8.3 million.
See the SBFM income statement, the SBFM chart for price history, or the SBFM stock overview for the latest quote and news.
SBFM key metrics FAQ
What is Sunshine Biopharma's return on equity?
Sunshine Biopharma's return on equity (ROE) was −25.7% in fiscal 2025: net income of -$6.0 million on average shareholders' equity of $23.3 million.
What is Sunshine Biopharma's ROIC?
Sunshine Biopharma's return on invested capital was −24.0% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does Sunshine Biopharma have?
Sunshine Biopharma had total debt of $0.8 million at the end of fiscal 2025, a debt-to-equity ratio of 0.04 and more cash than debt.
What is Sunshine Biopharma's current ratio?
Sunshine Biopharma's current ratio was 4.17 at the end of fiscal 2025: current assets were 4.17 times current liabilities.